January 18, 2023 06:40 AM EST

Ready to expand, GenScript raises $224M for CDMO focused on antibodies, cell and gene therapies

Amber Tong

Senior Editor

China’s GenScript has brought in new investors to back its biologics-focused subsidiary — to the tune of $224 million.

GenScript, which is listed in Hong Kong, disclosed the Series C for GenScript ProBio in a filing. The new funds will help “build up manufacturing capacity, further research and development capabilities and opportunistically acquire assets” to develop ProBio’s contract development and manufacturing business, the mother company wrote.

Outsourcing channel feed

CVS will shut down clinical trials unit that it launched during Covid

CRO deal space continues to buzz as Genesis Drug Discovery buys JSS Medical Research

CRO Syneos Health to be acquired by a group of private equity firms for $7B+

On heels of Essex deal, CRO Emmes says it's planning to make more acquisitions this year

TandemAI raises $35M in Series A for small molecule discovery, wet labs

Pfizer was warned of Lyme study problems months ago, trial research startup's CEO tells employees

Flagship company teams up with Charles River for AI drug discovery

As clinical trials get more complex, software startup Faro bags $20M to help visualize them

Ready to expand, GenScript raises $224M for CDMO focused on antibodies, cell and gene therapies

Amber Tong

Senior Editor

Ready to expand, GenScript raises $224M for CDMO focused on antibodies, cell and gene therapies

Outsourcing channel feed

Ready to ex­pand, Gen­Script rais­es $224M for CD­MO fo­cused on an­ti­bod­ies, cell and gene ther­a­pies

Senior Editor

Ready to expand, GenScript raises $224M for CDMO focused on antibodies, cell and gene therapies